Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years

Vaccine

Volumn 24, Issue 35-36, 2006, Pages 6163-6171

  Black, Steven ^a   Friedland, Leonard R ^b   Schuind, Anne ^b   Howe, Barbara ^b  

^a KAISER PERMANENTE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

DTaP IPV; MMR; Pre school booster

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS INACTIVATED POLIOMYELITIS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IPOL; MEASLES MUMPS RUBELLA VACCINE; MMR; POLIOMYELITIS VACCINE; TETANUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DROWSINESS; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FUNCTIONAL DISEASE; GEOMETRY; HUMAN; IMMUNOGENICITY; INCIDENCE; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; JOINT SWELLING; MEASLES; NORMAL HUMAN; PAROTID GLAND DISEASE; PHASE 2 CLINICAL TRIAL; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SWELLING; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION;

ANTIBODIES; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS, SUBCUTANEOUS; MALE; MEASLES-MUMPS-RUBELLA VACCINE; POLIOVIRUS VACCINE, INACTIVATED;

EID: 33746799339     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.001     Document Type: Article

References (32)

1. Schmitt H.J., Booy R., Weil-Olivier C., Van Damme P., Cohen R., and Peltola H. Child vaccination policies in Europe: a report from the Summits of independent European vaccination experts. Lancet Infect Dis 3 (2003) 103-108
2. Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 2002;51(RR-2):1-35.
3. Therre H., and Baron S. Pertussis immunisation in Europe-the situation in late 1999. Euro Surveill 5 (2000) 6-10
4. Centers for Disease Control and Prevention. Pertussis, United States, 1997-2000. MMWR 2002;51:73-6.
5. von Konig C.H., Halperin S., Riffelmann M., and Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2 (2002) 744-750
6. Tan T., Trindade E., and Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J 24 Suppl. (2005) S10-S18
7. Impfempfehlungen der ständigen impfkom-mission (STIKO) am Robert-Koch-Institut. Stand: January 2000. Dt Ärzteblatt 2000; 16(Suppl.):3-18.
8. Gibbons V. Addition of acellular pertussis to preschool booster in the United Kingdom. http://www.eurosurveillance.org/ew/2001/011115.asp; 2005 [accessed July 28, 2005].
9. Andersen P. Danish childhood vaccination programmer modified to include pertussis and polio boosters at 5 y of age. http://www.eurosurveillance.org/ew/2003/030828.asp.
10. Advisory Committee on Immunization Practices. ACIP recommends adolescent vaccination for tetanus, diphtheria and pertussis vaccine. Available at: http://www.cdc.gov/nip/pr/pr_tdap_jun2005.htm; 2005 [accessed July 28, 2005].
11. Andre F.E. Development and clinical application of new polyvalent combined paediatric vaccines. Vaccine 17 (1999) 1620-1627
12. Bogaerts H. The future of childhood immunizations: examining the European experience. Am J Manag Care 9 Suppl. (2003) S30-S36
13. Centers for Disease Control and Prevention. Combination vaccines for childhood immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR 1999;48(RR-5):1-15.
14. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care 9 Suppl. (2003) S6-S12
15. Rennels M.B. Combination vaccines. Pediatr Infect Dis J 21 (2002) 255-257
16. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 (1985) 213-226
17. Marshall H., Nolan T., Roberton D., et al. A comparison of booster immunisation with a combination DTaP-IPV vaccine or DTaP plus IPV in separate injections when co-administered with MMR at age 4-6 years. Vaccine 24 (2006) 6120-6128
18. Nilsson L., Faldella G., Jacquet J.M., Storsaeter J., Silfverdal S.A., and Ekholm L. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age. Scand J Infect Dis 37 (2005) 221-229
19. Pichichero M., Edwards K., Anderson E., et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four to six year old children. Pediatrics 105 1 (2000). http://www.pediatics.org/cgi/content/full/105/1/e11 Available at:
20. Rennels M.B. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis 14 (2003) 196-198
21. Rennels M.B., Deloria M., Pichichero M., et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105 1 (2000). http://www.pediatics.org/cgi/content/full/105/1/e12 Available at:
22. Skowronski D., Remple V., Macnabb J., et al. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity and anticipated impact. Pediatrics 112 (2003) e453. http://www.pediatics.org/cgi/content/full/112/6/e453 Available at:
23. Woo E., Burwen D., Gatumu S., Ball R., and the VAERS working group. Extensive limb swelling after immunization: reports to the vaccine adverse event reporting system. Clin Infect Dis 37 (2003) 351-358
24. Centers for Disease Control. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: Supplemental Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(RR-13):1-8.
25. Ryan E.J., Nilsson L., Kjellman N., Gothefors L., and Mills K.H. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin Exp Immunol 121 (2000) 193-200
26. Jacquet J.M., Begue P., Grimprel E., et al. Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review. Vaccine 24 13 (2006) 2440-2448
27. ® package insert, August 2003.
28. Halperin S., Scheifele D., Barreto L., et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J 18 (1999) 772-779
29. Halperin S., Scheifele D., Mills E., et al. Nature, evolution, and appraisal of adverse events and antibody response associate with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine 21 (2003) 2298-2306
30. Scheifele D.W., Halperin S.A., and Ferguson A.C. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine 19 (2001) 4720-4726
31. Tozzi A.E., Anemona A., Stefanelli P., et al. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics 107 2 (2001). http://www.pediatics.org/cgi/content/full/107/2/e25 Available at:
32. Yeh S.H., and Ward J.I. Strategies for development of combination vaccines. Pediatr Infect Dis J 20 (2001) S5-S9